Integration in Psychedelic-Assisted Treatments: Recurring Themes in Current Providers’ Definitions, Challenges, and Concerns

The investigators conducted semi‑structured interviews with 30 practitioners who described themselves as providers of psychedelic integration. Participants lived primarily in the United States (N = 21), with others in Canada (5), Mexico (2), Costa Rica (1), and Trinidad and Tobago (1). Ages ranged from 26 to 69 (M = 40.66, SD = 12.08). Gender identities included 11 female, 15 male, two nonbinary, and two two‑spirit/fluid. Most identified as White (22); others identified as mixed race (5), Latin (2), or Asian (1). Educational backgrounds spanned high school through doctorate, with the modal group holding or pursuing a master's in clinical or counselling psychology or social work (14). Reported experience providing integration averaged 4.53 years (range 0.33–26). All participants reported extensive integration training from mentors; 16 (53.3%) had completed a certification programme and 13 (43.3%) had formal affiliation with a shamanic tradition. Providers reported working with multiple substances, most commonly psilocybin (24; 80%), MDMA (17; 56.7%), and ketamine (14; 46.7%), among others. Recruitment used social media, mailing lists, and professional networks; 88 potential respondents initially replied, 31 agreed to be interviewed and one was excluded for doing primarily assessment rather than integration, leaving the final N = 30. Participants received a US$50 gift certificate. Procedures were approved by an Institutional Review Board. Interviews were audio recorded via Zoom or telephone, transcribed verbatim, and averaged 69 minutes (SD = 16). Qualitative analysis followed a grounded‑theory style. Three authors (including the interviewer) read all transcripts and iteratively identified themes; two authors independently generated theme lists, met to reconcile terms and definitions, and refined operational definitions for coding. Two independent coders, with no prior contact with participants and who did not develop the codes, then coded all transcripts for presence/absence of themes. Inter‑rater reliability was strong for 19 of 21 proposed codes (Cohen's κ ranged from .857 to 1.00); two affect‑related codes failed to reach acceptable reliability (κ = .524 and .359) and were dropped. Quantitative analyses converted qualitative codes into binary counts and used nonparametric methods (chi‑square tests) to examine covariation among themes and associations with demographic or training variables. The authors report no a priori hypotheses about specific associations.

Coding produced 19 reliably identified themes across three broad categories: definitions of integration, challenges encountered in practice, and concerns about the field. The authors synthesised a working definition from interview data: integration as a bridge linking the psychedelic experience to everyday life that helps clients make personalised meaning, fosters lasting behaviour change, and promotes a sense of wholeness or completion; more than 70% of interviewees endorsed at least one facet of this multifaceted definition. Seven reliably coded definitions emerged. The most frequently endorsed described integration as a bridge between the psychedelic state and daily living. Other common definitions emphasised meaning‑making, the role of integration in producing enduring change, the personalised (ideographic) nature of integration, the importance of beginning integration during preparation, and the idea that integration can be an ongoing or lifelong process. A statistically significant association appeared between two definitions: participants who defined integration as a bridge were more likely to also describe it as personalised/ideographic (χ2(1, N = 30) = 31.92, p < .001). Definitions were otherwise orthogonal to demographic variables, clinical orientation, years in practice, and certification status. Four reliably coded challenges to practising integration were reported. The most common was client nonresponse (clients who do not improve despite treatment), followed by client resistance to engagement, therapist self‑care concerns, and stigma associated with psychedelic therapies. Challenges did not covary with one another, but those who mentioned nonresponse were also more likely to emphasise that integration should begin during the preparation stage (χ2(1, N = 30) = 31.53, p < .001). Five reliably coded concerns about the broader field were identified: commercialisation of psychedelic therapy, the risk that psychedelics will be viewed as a panacea, insufficient attention to cultural appropriation, power differentials and the potential for provider misuses of authority, and affordability/access issues. For example, affordability concerns were noted by 13 participants (43.3%). Additional themes that appeared frequently included worries about therapists' personal use of psychedelics, the importance of a professional community for integration providers, and a preference for a nondirective, client‑led approach; two‑thirds of participants (20 of 30; 66.7%) spontaneously mentioned the nondirective stance. One participant summarised that stance as, "It's more about guiding them through their experience of where they get to be and where they want to take the journey." Reliability metrics were reported: 19 of 21 proposed codes achieved acceptable Cohen's κ (.857–1.00), and subsequent analyses used the presence/absence of themes as coded by either independent coder.

Earleywine and colleagues interpret their findings as evidence that integration is widely viewed by current providers as a bridging, personalised process that links the psychedelic event to sustained changes in daily life. Interviewees most commonly reported client‑centred concerns such as nonresponse and resistance, and provider‑centred issues including self‑care needs and the desire for peer support. At the field level, the predominating worry was commercialisation, accompanied by fears of cultural appropriation, power imbalances, and limited access due to cost. The authors propose organising future work around two domains—client‑related and provider‑related issues—and suggest that this framework could guide efforts to predict who benefits from psychedelic treatment and how integration practices might be modified to improve outcomes. They highlight the potential value of therapist communities and supervision to protect provider wellbeing and to share approaches for difficult cases. Parallels with motivational interviewing are discussed: many providers spontaneously endorsed nondirective, client‑centred techniques consistent with motivational interviewing, and the authors recommend exploring whether mechanisms such as "change talk" might mediate benefits of integration. Several limitations acknowledged by the study team temper the conclusions. The sample, while diverse on some dimensions, was limited to English‑speaking practitioners reachable online and willing to participate for modest compensation; this could under‑represent non‑English speakers, those without internet access, and practitioners who declined for intellectual property or compensation reasons. The interview format emphasised spontaneous mentions, so endorsement rates may underestimate practitioners' broader views. Two affect‑related codes were dropped due to low inter‑rater reliability, and the qualitative design does not link specific integration practices to client outcomes. The authors therefore call for further work: more targeted interviews, stratified sampling to include larger samples of people of colour, detailed questioning about techniques, coding of recorded integration sessions (for example, to capture change talk), and ultimately controlled trials or outcome studies that test whether different definitions or approaches to integration influence therapeutic benefit. Despite these caveats, the authors argue that identifying 19 recurrent domains provides a useful starting point for standardising research on integration, developing training and supervision resources, and designing studies to test which elements of integration most strongly predict clinical improvement.